AUG Therapeutics, LLC /
Avalo Therapeutics, Inc.
AUG Therapeutics to purchase Avalo’s 800 Series assets
What happened
AUG Therapeutics, LLC agreed to buy Avalo Therapeutics, Inc.’s rights and related assets for AVTX-801, AVTX-802 and AVTX-803. The transaction includes an upfront payment of $150,000 and contingent milestone payments.
The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions, including certain third-party consents.
The source
Everything on this page comes from the source below.
AUG Therapeutics to purchase Avalo’s 800 Series assets
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Expected close
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly